AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01605409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency cardiopulmonary bypass under ongoing CPR
Description: Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT.
Study NCT01605409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ACLS
Description: Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible.
Study NCT01605409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACLS
Description: Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible.
Study NCT02000089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
Study NCT02000089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
Study NCT02000089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tumor marker gene test with CA19-9
Description: A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
Study NCT00667940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rater training workshop
Description: Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
Study NCT03427814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg orally twice daily
Study NCT03427814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg orally twice daily
Study NCT03978598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel
Description: Immediate v. Standard insertion.
Study NCT03978598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Immediate v. Standard insertion.
Study NCT03978598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexplanon
Description: Implant.
Study NCT03978598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexplanon
Description: Implant.
Study NCT03690401 — intervention group
Intervention type: DEVICE
Intervention: SOZO Device
Description: SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
Study NCT03690401 — intervention group
Intervention type: DEVICE
Intervention: DEXA Scan
Description: DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
Study NCT00600106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1/10 NA/EE
Description: Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
Study NCT00600106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg placebo
Study NCT04053855 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urinary sample
Description: Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
Study NCT02810288 — intervention group
Intervention type: BEHAVIORAL
Intervention: Voluntarily response all items in the questionnaire.
Description: The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician.
Study NCT06300749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Cervical Manipulation
Description: In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae.
Study NCT06300749 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Technique Practice
Description: The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
Study NCT01277705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine
Description: Intramuscular, single
Study NCT01277705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Intramuscular, single dose
Study NCT01277705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' IPV vaccine
Description: Intramuscular, single dose
Study NCT01277705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Revaxis®
Description: Intramuscular, single dose
Study NCT06547697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration
Study NCT00869492 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: benzoyl peroxide
Description: benzoyl peroxide %5 solution once dailly
Study NCT00869492 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nadifloxacine
Description: Nadifloxacine 1% cream twice dailly
Study NCT00795444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
Study NCT01282242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV rt-PA
Description: open-label
Study NCT01375127 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Subjects who previously took 15 mg BID or 30 mg BID
Study NCT01375127 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
Study NCT02200757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin
Description: 230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
Study NCT02200757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
Study NCT00551434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine 21 g daily
Study NCT00551434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine and creatine
Description: L-arginine
Study NCT00551434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: l-arginine 9 g daily
Study NCT00551434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo, double
Description: placebo
Study NCT01631201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifalazil 25 milligram
Description: Single dose of 25 milligram rifalazil to be administered on Day 1.
Study NCT01631201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1 gram
Description: Single dose of Azithromycin 1 gram to be administered on Day 1.
Study NCT03127917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline capsules given at 6 g/day
Study NCT03127917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin capsules given as placebo
Study NCT01404143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subscapularis Tenotomy
Description: After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
Study NCT03234075 — intervention group
Intervention type: OTHER
Intervention: Regional organization for promotion of renal transplantation
Description: Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator
Study NCT01092364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: Behavioral lifestyle intervention for weight loss, compared to advice-only control.
Study NCT04011137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Arm-cranking exercise
Study NCT00951691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced acute medical rehabilitation
Description: Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data.
Study NCT00951691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment with physical and occupational therapies
Study NCT01614522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 500mg BID
Study NCT02650193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP-130
Description: Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
Study NCT00470873 — intervention group
Intervention type: DRUG
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
Study NCT03164122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of microfat and plasma rich platelet PRP
Description: intra-articular injections
Study NCT03164122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI 3T
Study NCT02626299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid - 800mg/day
Description: All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
Study NCT02626299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid - 200mg/day
Description: The control group will receive 1-capsule containing 200 mg DHA/d.
Study NCT02626299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docosahexaenoic acid - 200mg/day
Description: The control group will receive 1-capsule containing 200 mg DHA/d.
Study NCT02626299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
Study NCT02334137 — intervention group
Intervention type: BEHAVIORAL
Intervention: iPad app
Description: Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others.
Study NCT02334137 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educator sessions
Description: A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
Study NCT02334137 — intervention group
Intervention type: BEHAVIORAL
Intervention: Retinal photos
Description: A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
Study NCT00589602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood lymphocyte therapy
Description: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be >0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be >2 x 106 cells/kg.
Study NCT00589602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation
Study NCT00589602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood stem cell transplantation
Study NCT00589602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation (TBI)
Description: Treatment will be delivered using 6MV photons twice daily for 3 days
Study NCT03952689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serenno Medical Automatic Urine Output measuring device
Description: Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count).
Study NCT04218513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection
Description: 30 min intravenous infusion
Study NCT04218513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Injection
Description: 30 min intravenous infusion
Study NCT04218513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Aminoethanesulfonic Acid Injection
Description: 30 min intravenous infusion
Study NCT03391375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 & AIDSVAX B/E
Description: DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
Study NCT04143789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-002
Description: Dose escalation
Study NCT03062670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retreat
Description: Full day off-site training session
Study NCT03552809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gigaa Cheese 810 nm Diode Laser
Description: Diode Laser assisted frenectomy operation.
Study NCT03552809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Frenectomy Operation
Description: Frenectomy operation performed by surgical blades with suturing.
Study NCT03857464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Near Patient Testing
Description: Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
Study NCT03857464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SOP for C. difficile diagnostics
Description: Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
Study NCT00748111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample and thrombus sample
Study NCT00343395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVANDAMET
Description: 2/500 mg
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: Patient will complete symptom survey prior to starting the study drugs.
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Compliance Phone Call
Description: The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medication Compliance Phone Call
Description: The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
Study NCT03781596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopy while on study drug
Description: Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
Study NCT03781596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy while on study drug
Description: Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
Study NCT03781596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.